You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

TYK2

Showing 1 - 25 of 47
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Cicatricial Alopecia Trial in New York (PF-06700841, Placebo)

Recruiting
  • Cicatricial Alopecia
  • New York, New York
    Icahn School of Medicine at Mount Sinai
Aug 16, 2022

Dermatomyositis Trial in Orlando, Plantation (Brepocitinib, Placebo)

Recruiting
  • Dermatomyositis
  • Orlando, Florida
  • +1 more
Jun 24, 2022

Hidradenitis Suppurativa Trial in Boston (Deucravacitinib, Placebo)

Not yet recruiting
  • Hidradenitis Suppurativa
  • Boston, Massachusetts
    Beth Israel Deaconess Medical Center
Aug 10, 2023

Psoriasis Trial in Canada, United States (VTX958, Placebo)

Recruiting
  • Psoriasis
  • Hot Springs, Arkansas
  • +6 more
Jan 19, 2023

Psoriasis Trial (BMS-986322, Placebo)

Not yet recruiting
  • Psoriasis
  • (no location specified)
Feb 7, 2023

Healthy Volunteers Trial (TY-9591)

Not yet recruiting
  • Healthy Volunteers
  • (no location specified)
May 15, 2023

Solid Tumor, Adult Trial in Beijing (TY-2699a)

Not yet recruiting
  • Solid Tumor, Adult
  • Beijing, Beijing, China
    National Cancer Center/Cancer Hospital, Chinese Academy of Medic
May 18, 2023

Locally Advanced Solid Tumor, Metastatic Solid Tumor Trial in Providence (TY-2136b)

Not yet recruiting
  • Locally Advanced Solid Tumor
  • Metastatic Solid Tumor
  • Providence, Rhode Island
    Rhode Island Hospital, Brown University
Mar 2, 2023

Safety and Tolerability Trial in Glendale (Experimental drug: ESK-001, Placebo)

Recruiting
  • Safety and Tolerability
  • Experimental drug: ESK-001
  • Placebo
  • Glendale, California
    Alumis Central site
Jun 20, 2022

Healthy Volunteers, Adult, Pharmacokinetics Trial in Brussels (Ritlecitinib)

Not yet recruiting
  • Healthy Volunteers
  • +2 more
  • Brussels, Bruxelles-capitale, Région DE, Belgium
    Brussels Clinical Research Unit
May 1, 2023

Vitiligo, Generalized Trial (Baricitinib)

Not yet recruiting
  • Vitiligo, Generalized
  • (no location specified)
Jul 7, 2023

Psoriatic Arthritis Trial in Duncansville, South Charleston (Dose A VTX958, Dose B VTX958, Placebo)

Recruiting
  • Psoriatic Arthritis
  • Dose A VTX958
  • +2 more
  • Duncansville, Pennsylvania
  • +1 more
Feb 4, 2023

Ulcerative Colitis Chronic Moderate, Ulcerative Colitis Chronic Severe Trial in Spain (OST-122, Placebo)

Completed
  • Ulcerative Colitis Chronic Moderate
  • Ulcerative Colitis Chronic Severe
  • Santiago de Compostela, A Coruña, Spain
  • +15 more
Jan 11, 2023

Psoriasis Vulgaris Trial in San Francisco (deucravacitinib)

Not yet recruiting
  • Psoriasis Vulgaris
  • San Francisco, California
    University of California, San Francisco
May 4, 2023

RET-altered Non Small Cell Lung Cancer, Medullary Thyroid Cancer, RET-altered Papillary Thyroid Cancer Trial in Chang chun

Not yet recruiting
  • RET-altered Non Small Cell Lung Cancer
  • +3 more
  • Chang chun, Jilin, China
    Jinlin Province Cancer Hosipital
Dec 21, 2022

Crohn Disease Trial in Tyler (VTX958, VTX958 Placebo)

Recruiting
  • Crohn Disease
  • Tyler, Texas
    Local Site # 840101
Jan 17, 2023

NSCLC, EGFR Activating Mutation, Brain Metastases Trial in Beijing (TY-9591, Osimertinib)

Not yet recruiting
  • NSCLC
  • +2 more
  • Beijing, Beijing, China
    National Cancer Center/Cancer Hospitial,Chinese Academy of Medic
Jul 9, 2023

Immune Function and the Progression to T1D

Recruiting
  • Type 1 Diabetes
  • blood draw
  • Gainesville, Florida
    Kieran McGrail
Jun 12, 2023

Ulcerative Colitis Trial in San Antonio (TLL018, Placebo)

Withdrawn
  • Ulcerative Colitis
  • San Antonio, Texas
    Gastroenterology Research of San Antonio (GERSA)
May 9, 2022

NSCLC, EGFR Activating Mutation Trial in Changsha, Shanghai (TY-9591, Osimertinib, Osimertinib)

Recruiting
  • NSCLC
  • EGFR Activating Mutation
  • Changsha, Hunan, China
  • +1 more
Dec 6, 2022

NSCLC, EGFR Activating Mutation, Brain Metastases Trial in Beijing (TY-9591 Tablets)

Recruiting
  • NSCLC
  • +3 more
  • TY-9591 Tablets
  • Beijing, Beijing, China
    National Cancer Center/Cancer Hospitial,Chinese Academy of Medic
May 14, 2022

Systemic Lupus Erythematosus Trial in Worldwide (Deucravacitinib, Placebo)

Recruiting
  • Systemic Lupus Erythematosus
  • Anniston, Alabama
  • +88 more
Jan 25, 2023

Systemic Lupus Erythematosus Trial in Worldwide (Deucravacitinib, Placebo)

Recruiting
  • Systemic Lupus Erythematosus
  • La Jolla, California
  • +91 more
Jan 24, 2023

Healthy Volunteers Trial in Changsha (TY-9591 Tablets under Fasted Condition - Arm1, Osimertinib Mesylate Tablets under Fasted

Completed
  • Healthy Volunteers
  • TY-9591 Tablets under Fasted Condition - Arm1
  • +5 more
  • Changsha, Hunan, China
    Hunan Provincial Tumor Hospital
Dec 6, 2022

COVID-19 Trial in Chengdu (VV116+SOC, SOC)

Recruiting
  • COVID-19
  • Chengdu, Sichuan, China
    Chengdu Zenitar Biomedical Technology Co., Ltd
Feb 3, 2023